NovaDigm Therapeutics' Series B Round

NovaDigm Therapeutics raised a round of funding on October 03, 2013. Investors include Domain Associates.

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is…

Articles about NovaDigm Therapeutics' Series B Round: